olaparib,enzalutamide,abiraterone,Niraparib,Prednisone
Astrazeneca,Merck,Janssen,pfizer,Astellas
['prostate']
efficacy of parp inhibitors in patients with metastatic castration resistant prostate carcinoma: a meta-analysis of phase iii randomized controlled trials: no significant difference was observed in overall survival between the two groups. #asco23
Medicina Interna - Oncología, Clínica Astorga. Profesor titular @upbcolombia Medellín / Colombia #OncTwitter “De los expertos, líbrame Señor🙏🏻”